JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran
Payandeh, Mehrdad; Shazad, Babak; Sadeghi, Masoud; Shahbazi, Maryam;
  PDF(new window)
 Abstract
In the patients with metastatic colorectal cancer (mCRC), RAS testing is the first step to identify those that could benefit from anti-EGFR therapy. This study examined associations between KRAS mutations and clinicopathological and survival data in Iranian patients with mCRC. Between 2008 to2015 in a retrospective study, 83 cases of mCRC were referred to the Clinic of Medical Oncology. The mean follow-up was 45 months that there were 27 deaths. The 3 patients that did not complete follow-up were censored from the study. KRAS and NRAS were analyzed using allele-specific PCR primers and pyrosequencing in exons 2, 3 and 4. Multivariate survival analysis using Cox`s regression model was used for affecting of variables on overall survival (OS). The mean age at diagnosis for patients was 57.7 (range, 18 to 80 years) and 61.4% were male. There was no significant different between prognostic factors and KRAS mutation with wild-type. Also, There was no significant different between KRAS mutation and KRAS wild-type for survival, but there was a significant different between KRAS 12 and 13 mutations for survival (HR 0.13, 95% CI 0.03-0.66, P
 Keywords
KRAS;NRAS;metastatic colorectal cancer;survival;western Iran;
 Language
English
 Cited by
 References
1.
Allegra CJ, Rumble RB, Hamilton SR, et al (2016). Extended ras gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: american society of clinical oncology provisional clinical opinion update 2015. J Clin Oncol, 34, 179-85. crossref(new window)

2.
Al-Kuraya KS (2009). KRAS and TP53 mutations in colorectal carcinoma. Saudi J Gastroenterol, 15, 217-9. crossref(new window)

3.
Brink M, Weijenberg MP, de Goeij AF, et al (2005). Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. Int J Cancer, 114, 824-30. crossref(new window)

4.
Bokemeyer C, Bondarenko I, Makhson A, et al (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 27, 663-71. crossref(new window)

5.
Inoue Y, Saigusa S, Iwata T, et al (2012). The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep, 28, 1579-84.

6.
Lievre A, Bachet J, Le Corre D, et al (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66, 3992-5. crossref(new window)

7.
Liu X, Jakubowski M, Hunt JL (2011). KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol, 135, 245-52. crossref(new window)

8.
Li Z, Chen Y, Wang D, et al (2012). Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. J Int Med Res, 40, 1589-98. crossref(new window)

9.
Margonis GA, Kim Y, Spolverato G, et al (2015). Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg, 150, 722-9. crossref(new window)

10.
Modest DP, Stintzing S, Laubender RP, et al (2011). Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs, 22, 913-8. crossref(new window)

11.
Neumann J, Zeindl-Eberhart E, Kirchner T, et al (2009). Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract, 205, 858-62. crossref(new window)

12.
Omidifar N Md, Geramizadeh B Md, Mirzai M Ms (2015). K-ras mutation in colorectal cancer, a report from southern Iran. Iran J Med Sci, 40, 454-60.

13.
Payandeh M, Sadeghi E, Sadeghi M, et al (2015a). Chronic myeloid leukemia in patient with local recurrence colon cancer: a case report. Int J Cancer Research, 11, 197-200. crossref(new window)

14.
Payandeh M, Sadeghi M, Sadeghi E, et al (2015b). Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. Am J Cancer Prevent, 3, 19-22.

15.
Payandeh M, Sadeghi M, Sadeghi E (2016). The report of KRAS mutation and NRAS wild-type in a patient with thyroid metastasis from colon cancer: a rare case report. Iran J Pathol, 11, 71-5.

16.
Russo A, Rizzo S, Bronte G, et al (2009). The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncol, 77, 57-68. crossref(new window)

17.
Roock WD, Vriendt VD, Normanno N, et al (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol, 12, 594-603. crossref(new window)

18.
Sameer AS, Chowdhri NA, Abdullah S, et al (2009). Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer, 46, 219-25. crossref(new window)

19.
Shen H, Yuan Y, Hu HG, et al (2011). Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol, 17, 809-16. crossref(new window)

20.
Tan C, Du X (2012). KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol, 18, 5171-80.

21.
Wilson PM, Labonte MJ, Lenz HJ (2010). Molecular markers in the treatment of metastatic colorectal cancer. Cancer J, 16, 262-72. crossref(new window)

22.
Yokota T, Shibata N, Ura T, et al (2010). Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/Vraf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. Transl Res, 156, 98-105. crossref(new window)